These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32813910)

  • 1. Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: A micro-simulation study of 230 scenarios.
    Getaneh AM; Heijnsdijk EAM; Roobol MJ; de Koning HJ
    Cancer Med; 2020 Oct; 9(20):7742-7750. PubMed ID: 32813910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
    Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
    J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
    Callender T; Emberton M; Morris S; Eeles R; Kote-Jarai Z; Pharoah PDP; Pashayan N
    PLoS Med; 2019 Dec; 16(12):e1002998. PubMed ID: 31860675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
    Gulati R; Gore JL; Etzioni R
    Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men.
    Teoh JY; Leung CH; Wang MH; Chiu PK; Yee CH; Ng CF; Wong MC
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):615-621. PubMed ID: 32606435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for prostate cancer in the US? Reduce the harms and keep the benefit.
    de Carvalho TM; Heijnsdijk EA; de Koning HJ
    Int J Cancer; 2015 Apr; 136(7):1600-7. PubMed ID: 25123412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
    Ten Haaf K; Tammemägi MC; Bondy SJ; van der Aalst CM; Gu S; McGregor SE; Nicholas G; de Koning HJ; Paszat LF
    PLoS Med; 2017 Feb; 14(2):e1002225. PubMed ID: 28170394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Prostate-Specific Antigen Screening Among Chinese Men.
    Zhao G; Shao Y; Zhang N; Wang J; Yuan L; Sun X; Shi L
    Value Health Reg Issues; 2020 May; 21():272-279. PubMed ID: 32402819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
    Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer.
    Callender T; Emberton M; Morris S; Pharoah PDP; Pashayan N
    JAMA Netw Open; 2021 Mar; 4(3):e2037657. PubMed ID: 33704474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.
    Pataky R; Gulati R; Etzioni R; Black P; Chi KN; Coldman AJ; Pickles T; Tyldesley S; Peacock S
    Int J Cancer; 2014 Aug; 135(4):939-47. PubMed ID: 24443367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of prostate cancer screening using the Stockholm3 test.
    Karlsson AA; Hao S; Jauhiainen A; Elfström KM; Egevad L; Nordström T; Heintz E; Clements MS
    PLoS One; 2021; 16(2):e0246674. PubMed ID: 33630863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Cost-Utility Analysis of Prostate Cancer Screening in Australia.
    Keller A; Gericke C; Whitty JA; Yaxley J; Kua B; Coughlin G; Gianduzzo T
    Appl Health Econ Health Policy; 2017 Feb; 15(1):95-111. PubMed ID: 27757918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
    Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
    JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
    Draisma G; Etzioni R; Tsodikov A; Mariotto A; Wever E; Gulati R; Feuer E; de Koning H
    J Natl Cancer Inst; 2009 Mar; 101(6):374-83. PubMed ID: 19276453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models.
    Sanghera S; Coast J; Martin RM; Donovan JL; Mohiuddin S
    BMC Cancer; 2018 Jan; 18(1):84. PubMed ID: 29347916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study.
    Getaneh AM; Heijnsdijk EAM; de Koning HJ
    Sci Rep; 2021 Jan; 11(1):1801. PubMed ID: 33469144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
    Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
    PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis.
    Martin AJ; Lord SJ; Verry HE; Stockler MR; Emery JD
    Med J Aust; 2013 Jun; 198(10):546-50. PubMed ID: 23725269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.